Search clinical trials for: Atogepant 60 mg

Total 10433 results

Allergan

Completed

Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. (ELEVATE)

Episodic Migraine

United States, Australia, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Russian Federation, Spain, Sweden, United Kingdom
Allergan

Completed

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

Chronic Migraine

United States, Australia, Canada, China, Czechia, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Spain, Sweden, Taiwan, United Kingdom
AbbVie

Active, not recruiting

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

Chronic Migraine | Episodic Migraine

United States, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Spain, Taiwan, United Kingdom
AbbVie

Active, not recruiting

A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine

Chronic Migraine | Episodic Migraine

Japan
Allergan

Completed

Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine

Chronic Migraine

China
Vifor (International) Inc.
Labcorp Drug Development Inc

Withdrawn

Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia

Beta-Thalassemia

United States, Bulgaria, Israel
Grünenthal GmbH

Completed

A Clinical Study in Healthy Women Which Aims to Explore the Intestinal Uptake of Two Different Tablets of GRTA9906 Into the Body and the Effect of Food on it

Pain | Chronic Pain | Neuropathic Pain | Visceral Pain

Germany
AbbVie

Recruiting

Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine (Release)

Migraine

Japan
Allergan

Completed

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

Migraine, With or Without Aura

United States
AbbVie

Enrolling by invitation

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine

Episodic Migraine

United States, Canada, Denmark, Hungary, Italy, Poland, Puerto Rico, Spain, United Kingdom, Israel, Japan, Sweden
AbbVie

Recruiting

Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity in Adult Participants With Migraine (ECLIPSE)

Migraine

United Kingdom
AbbVie

Recruiting

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine (Kaleidoscope)

Episodic Migraine

United States, Puerto Rico, Hungary, Spain, Canada, Netherlands, Israel, Sweden, Poland, France, Denmark, Japan, United Kingdom, Italy, Romania, Belgium
Suzhou Kintor Pharmaceutical Inc,

Completed

Phase II Study Evaluating the Efficacy and Safety of KX-826

Androgenetic Alopecia (AGA)

China
Sobi, Inc.

Terminated

Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure

Thrombocytopenia

United States
H. Lundbeck A/S

Completed

Bioequivalence Study of Idalopirdine Tablets 60 mg

Healthy

United Kingdom
IRCCS San Raffaele Roma

Not yet recruiting

Atogepant in Real Life in Italy (GIANT) (GIANT)

Migraine, Prophylaxis
GlaxoSmithKline

Completed

Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)

Arthritis, Rheumatoid

Spain, Germany, Russian Federation, United Kingdom, Italy, Poland
Hoffmann-La Roche

Recruiting

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.

Huntington Disease

United States, Australia, Argentina, Canada, Germany, Italy, Spain, France, United Kingdom, Portugal, New Zealand, Austria, Poland, Switzerland, Denmark
PHARMENTERPRISES LLC

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers

Influenza | Acute Respiratory Infection

Russian Federation
Allergan

Completed

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

Episodic Migraine

United States
H. Lundbeck A/S

Completed

Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function

Alzheimer Disease

Germany
University of Bologna
Ipsen; Bioikos Ambiente Srl; AOU S.Orsola Malpighi-Unit of Oncologic Molecular... and other collaborators

Unknown

Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)

Non Small Cell Lung Cancer

Italy
Allergan

Completed

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

Episodic Migraine

United States
University of Washington
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest (SNOCAT)

Out-Of-Hospital Cardiac Arrest

United States
Shionogi
Hormos Medical; QuatRx Pharmaceuticals

Completed

A Clinical Study to Evaluate the Safety of Ospemifene

Atrophy | Vaginal Diseases
Shionogi
Hormos Medical; QuatRx Pharmaceuticals

Completed

Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity

Atrophy | Vaginal Diseases
Guangzhou Magpie Pharmaceuticals Co., Ltd.

Not yet recruiting

A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets

Pulmonary Arterial Hypertension
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

Cellulite

United States
AbbVie

Completed

Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine

Migraine

United States
Bial R&D Investments, S.A.

Recruiting

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE)

Parkinson's Disease

United States, Spain, France, Italy, Netherlands, Germany, United Kingdom, Canada, Poland, Portugal, Sweden
GlaxoSmithKline

Completed

A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.

Schizophrenia

United Kingdom
AbbVie

Completed

Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine (TANDEM)

Episodic Migraine

United States
AbbVie

Completed

Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers

Healthy Volunteers

United States
Exelixis

Active, not recruiting

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER)

Medullary Thyroid Cancer

Australia, France, Israel, Spain, Russian Federation, Netherlands, Hungary, Korea, Republic of, Croatia, Italy, Canada, Poland, Romania, Sweden
Pfizer

Completed

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

Obesity | Overweight

United States
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

Lung Adenocarcinoma
GlaxoSmithKline

Completed

First Time in Human Study Using GSK2330672

Diabetes Mellitus, Type 2

United States
Hospital do Coracao

Completed

Antiviral Agents Against COVID-19 Infection (REVOLUTIOn)

COVID-19

Brazil
Istituto Clinico Humanitas

Recruiting

Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma (Immunocabo)

Hepatocarcinoma

Italy
AbbVie

Recruiting

Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

Chronic Migraine

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

Healthy

United States
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease

Huntington's Disease

Canada, United Kingdom, Germany
American University of Beirut Medical Center
Takeda

Completed

An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan

GERD | Proton Pump Inhibitor

Lebanon
AbbVie

Recruiting

Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine (TEMPLE)

Migraine

Belgium, Canada, Germany, Poland, Portugal, France, Italy, Hungary, Czechia, Israel, Austria, United Kingdom
Pfizer
Syneos Health

Completed

A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers

Healthy

Canada
UCB Japan Co. Ltd.

Completed

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Rheumatoid Arthritis

Japan, Korea, Republic of, Taiwan
Enteris BioPharma Inc.
Syneos Health; Parexel

Recruiting

Study to Evaluate the Pharmacodynamics and Efficacy of Leuprolide Tablets (Ovarest®) in Women With Endometriosis

Endometriosis

United States
Myanmar Oxford Clinical Research Unit
Medical Action Myanmar; Myanmar Liver Foundation

Withdrawn

Hepatitis C Treatment Study in Myanmar

Hepatitis C

Myanmar
Allergan

Completed

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

Episodic Migraine

United States
H. Lundbeck A/S

Completed

Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease (STAR Extension)

Alzheimer's Disease

Germany, United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, France, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Poland, Portugal, Romania, South Africa, Spain, Taiwan and more

3

Subscribe